Fig. 10

The 5-year overall survival (a), event-free survival (b), and cumulative incidence of relapse (c) by “late” vs. “early” Arm A → C patient reassignments, B-cell phenotype, treating “early, A → C” and “late, A → C” reassigned patients as separate stratifications. “N”: Day 29 MRD < 0.01%, no reassignment (solid dark blue line); “Y”: Day 29 MRD ≥ 0.01% and no reassignment (solid light blue line). All “N” subjects were Arm A induction (i.e. A → A group). All “Y” subjects were Arm C induction (i.e. C → C group but MRD ≥ 0.01% at day 29). “early, A → C”, which is depicted as a dashed dark blue line represents reassigned NCI-SR patients to Arm C early due to ≥ 5% bone marrow blasts at day 15 of induction; “late, A → C”, which is depicted as a dashed light blue line represents reassigned NCI-SR patients to post-induction Arm C due to < 5% blasts at day 15 but MRD ≥ 0.01% at day 29 of induction. Both overall survival and event-free survival showed a significant (p ≤ 0.05) effect if patients who began treatment on Arm A but were switched to Arm C were stratified separately as “early” vs. “late”. The “late, A → C” group had significantly better outcomes, which were similar to patients assigned to Arm A and had rapid early response at both assessment time points on day 15 and 29 of induction (A → A group)